AstraZeneca (NASDAQ:AZN) used its presentation at the J.P. Morgan Healthcare Conference to highlight strong 2025 performance, ...
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback